Austrian R
J Infect Dis. 1977 Aug;136 Suppl:S38-42. doi: 10.1093/infdis/136.supplement.s38.
Because of the continuing morbidity and mortality resulting from pneumococcal infection, a program was instituted to redevelop polyvalent vaccines consisting of capsular polysaccharides of Streptococcus pneumoniae. Vaccines containing 50 microgram each of the capsular polysaccharides of as many as 13 pneumococcal types have been shown to be safe, antigenic, and 78.5% effective in the prevention of type-specific putative pneumococcal pneumonia and of type-specific pneumococcal bacteremia in adults. In a population in which pneumococcal pneumonia predominated, the total incidence of radiologically confirmed pneumonia, irrespective of cause, was reduced by 54.3% by use of a tridecavalent vaccine. The efficacy of vaccine in the prevention of infection during the first two years of life is under investigation. The vaccine is recommended for those at high risk of pneumococcal infection or of a fatal outcome from such illness.
由于肺炎球菌感染持续导致发病和死亡，因此开展了一项计划，以重新研发由肺炎链球菌荚膜多糖组成的多价疫苗。已证明，含有多达13种肺炎球菌类型的荚膜多糖、每种50微克的疫苗是安全的、具有抗原性的，并且在预防成人特定类型的假定肺炎球菌肺炎和特定类型的肺炎球菌菌血症方面有效率达78.5%。在以肺炎球菌肺炎为主的人群中，使用十三价疫苗可使经放射学确诊的肺炎（无论病因）总发病率降低54.3%。该疫苗在预防两岁以下儿童感染方面的效果正在研究中。建议将该疫苗用于有肺炎球菌感染高风险或因该疾病导致致命后果风险高的人群。
